Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Top Ten Searches
post partum incontinence fibroid hpv colpotomy ovarian cyst curettage endometriosis intrauterine umbilical cordYour Article Summary
See Latest ArticlesAnti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)
Human Reproduction Update, 10/01/09
Marca AL et al. – As AMH may permit the identification of both the extremes of ovarian stimulation, a possible role for its measurement may be in the individualization of treatment strategies in order to reduce the clinical risk of ART along with optimized treatment burden. It is fundamental to clarify the cost/benefit of its use in ovarian reserve testing. Regarding the role of AMH in the evaluation of infertile men, AMH as single marker of spermatogenesis does not seem to reach a satisfactory clinical utility.
Today in Repro Endo - Infertility...keeping you current
Receive free subspecialty "5-minute updates" via email
Pregnancy and Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/16/09
Metformin: An old medication of new fashion in PCOS
European Journal of Endocrinology, 10/30/09
Use of Fertility Drugs and Risk of Uterine Cancer: Results From a Large Danish Population-based Cohort Study
American Journal of Epidemiology, 11/04/09
Sponsor
Article Search
Sponsor